Recently, the share price of Xiangxue Pharmaceutical has plummeted. After hitting an intraday high of 9.79 yuan on April 7, it fell all the way to 5.06 yuan/share on April 27, with a drop of 48.3 1% in 20 days, almost halved. According to relevant market data, Xiangxue Pharmaceutical's share price hit an intraday low of 5.06 yuan on 27th, the lowest since 2065438+February 24th, 2002.
The reporter of China Times contacted the securities affairs department of Xiangxue Pharmaceutical and sent an interview letter to the reporter about the overdue commercial tickets and the company's profit performance in 20021year. The relevant staff told the reporter that the interview letter had been received, but as of press time, Xiangxue Pharmaceutical did not reply.
Net profit fell sharply.
Under the epidemic situation, Xiangxue Pharmaceutical's flagship product, antiviral oral liquid, became the "drag bottle" of 202 1.
In 20021year, Xiangxue Pharmaceutical achieved revenue of 2.9765438 billion yuan, down 3.30% year-on-year; The net profit attributable to shareholders of listed companies turned from profit to loss of 688 million yuan, a sharp year-on-year decrease of 799.5438+0%; After deducting the non-homecoming net profit, the loss was 73,654.38+0 billion yuan, a significant decrease of 599.438+02% year-on-year.
For the reasons for the sharp decline in performance, Xiangxue Pharmaceutical said that due to the epidemic situation, market competition and other factors, the company's sales of proprietary Chinese medicines failed to meet expectations, sales revenue decreased and gross profit margin decreased. In order to alleviate the pressure of liquidity, financing efforts were intensified, and financial expenses increased greatly, resulting in a sharp decline in profits.
According to the annual report data, the company's operating cost in 20021year was 210.90 billion, up 5.4% year-on-year, while its operating income decreased by 3.3% year-on-year, and its gross profit margin decreased by 6. 1%. During the period, the expense rate was 32. 1%, an increase of 6.6% over the previous year.
It is worth noting that antiviral oral liquid, as the leading product of Xiangxue Pharmaceutical, suffered the most serious decline in sales, with a decrease of 47.50% compared with the previous year, and its operating income was only 654.38+80 billion yuan, with a decrease of 55.73% compared with the same period of the previous year, and suffered from Waterloo.
On the morning of April 20th, an announcement about the approval of clinical trial of TAEST 190 1 injection failed to save the share price of Xiangxue Pharmaceutical. According to the announcement, the application for clinical registration of the new drug TAEST 190 1 injection submitted by Sun Xiangxue Life Science and Technology (Guangdong) Co., Ltd. to the State Administration of Pharmaceutical Products from June 5438 to October 2022 has been approved for clinical trials. The day after the announcement, it closed at 6.53 yuan/share, down 3. 12%.